The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Enhancer of Zeste Homolog 2 (EZH2) is crucial for cancer stem cell maintenance.
• EZH2 overexpression/mutation correlates with aggressive tumors, drug resistance, and poor patient prognosis.

Purpose of the Study:

• To investigate the role of EZH2 in Sonic Hedgehog (SHH) medulloblastoma stem-like cells (MB-SLCs).
• To evaluate the efficacy of a novel EZH2 inhibitor, MC3629, in preclinical models of medulloblastoma.

Main Methods:

• Genetic suppression of EZH2 in mouse and human SHH MB-SLCs.
• In vitro assessment of MC3629's effects on proliferation, self-renewal, and apoptosis.
• In vivo evaluation of MC3629 in orthotopic xenograft mouse models of medulloblastoma.

Main Results:

• Genetic EZH2 suppression decreased H3K27me3 levels, proliferation, and self-renewal in SHH MB-SLCs.
• MC3629 inhibited SHH MB cell proliferation and self-renewal, inducing apoptosis in vitro.
• MC3629 treatment in vivo reduced tumor growth, promoted apoptosis, and decreased proliferation and stemness.

Conclusions:

• EZH2 is a druggable target for medulloblastoma treatment.
• MC3629 demonstrates significant preclinical efficacy against medulloblastoma by targeting EZH2.